Polynovo Limited · ASX:PNV
Polynovo — FY2025 Earnings Presentation
15 slides from Polynovo's earnings presentation, Aug 25, 2025
Slide 1: FY25 Results
FY25 Results (in conjunction with Appendix 4E) Accelerating Global Impact Join webcast 2PM AEST, 25 August 2025
Slide 2: NovoSorb: Regenerative Healing
NovoSorb: Regenerative Healing Macro to micro The NovoSorb matrix organises a large wound (macrowound) into a series of 46 interconnected small wounds markets (microwounds). The body easily heals small wounds, promoting organised, regenerative healing. 6 Cellular migration throughout the matrix mark
Slide 3: Features of the NovoSorb Matrix
Features of the NovoSorb Matrix Robust in the presence Generate a neodermis of infection 1,2 over exposed tendons and bones 3,4,5 Often retained while the infection is treated Offering alternative treatment for complex wounds Minimise contracture Dermal repair to and improve support limb salvage 5 c
Slide 4: NovoSorb: From Platform Technology to Products and New Indications
NovoSorb®: 402 From Platform Technology to Products and New Indications 284 Regulatory Product Thickness Date body 215 FDA (U.S.) NovoSorb MTX Up to 6 mm March 2025 149 NovoSorb BTM Up to 6 mm June 2025 91 TGA (Australia) NovoSorb MTX 2 mm March 2025 60 NovoSorb MTX 4 mm, 6 mm May 2025 CDSCO (India)
Slide 5: From Technology to Products: Highlights
From Technology to Products: Highlights PMA • The 3-month data review of all trial participants in the BARDA Pivotal trial is complete. A strategic review of new product development is • The optimal PMA submission strategy, which underway to optimise value creation, leverage requires submission afte
Slide 6: Financial Results
&B) PolyNovo Financial Results
Slide 7: Financial Year 2025 Group Highlights
Financial Year 2025 Group Highlights Commercial 28.9% Total 23.3% NPAT 151.2% Sales in FY25 Revenue in FY25 in FY25 129.2 13.2 118.6 104.8 92.0 5.3 59.6 66.5 FY23 FY23 FY24 FY25 -4.9 FY23 FY24 FY25 FY23 FY24 FY25 BARDA Revenue*: Operating Leverage: EBITDA**: A$8.6m, -22.8% Sales +28.9% A$11.2m, +209
Slide 8: Strong Global Momentum
Strong Global Momentum 27.6% EMEA FY25 51.9% sales growth UK FY25 sales growth 24.2% APAC FY25 sales growth 48.5% 28.7% Canada FY25 sales growth 21.2% Aus & NZ FY25 U.S. FY25 sales growth sales growth 8
Slide 9: Financial Year 2025 – Product Sales by Region
Financial Year 2025 – Product Sales by Region Highlights: Commercial sales 28.9% by market in FY25 • A$118.6m NovoSorb product sales up 28.9% on STLY. • Milestone achievements: 30.3 • November 2024: A$10.1m 23.4 • March 2025: A$11.9m • June 2025: A$12.8m 5.6 13.5 4.8 • Strong growth in U.S. sales of
Slide 10: Market Update: United States
Market Update: United States Highlights: NovoSorb MTX commercial US commercial product sales sales • 28.7% commercial sales growth • A$6.7m total FY25 NovoSorb MTX sales 6.7 88.4 • 58.2% order growth 68.7 • 43.3% units sold growth 4.6 46.1 • Profitable and strong positive cash flow 2.1 • Increased e
Slide 11: Market Update: Rest of World
Market Update: Rest of World ROW commercial product Global expansion Highlights: sales • Rest of World sales of A$30.3m, up 29.6% on FY25 STLY of A$23.4m. 30.3 • Canada $A1.9m (+48.5%), France $0.7m 23.4 (+378.8%), Turkey A$1.9m (+36.7%) and UK A$7.5m (+51.9%) • First NovoSorb BTM sales in Malaysia,
Slide 12: Capital Efficient Growth
Capital Efficient Growth Highlights: FY25 cash flow breakdown • Cash and cash equivalents as at 30 June 2025 were A$33.5m. • Cash flow from operations of A$15.6m for 2H25 compared to 1H25 outflow of (A$12.5m), total FY25 A$3.1m. • Cash flow from operations is expected to increase in FY26 as the prof
Slide 13: FY25 Financial Results and Balance Sheet
FY25 Financial Results and Balance Sheet Income Statement Balance Sheet ($m) FY25 FY24 Change % ($m) FY25 FY24 Change % Total revenue 129.2 104.8 23.3% Cash and cash equivalent 33.5 45.9 -27.0% Changes in inventories & WIP* (5.2) (5.6) -7.1% Trade and other receivables 24.4 20.7 17.9% Employee-relat
Slide 14: Outlook
Outlook Disciplined execution to drive superior patient outcomes, growth and profitability. Clinical and Product Strategic Expansion Operational Excellence • Robust NovoSorb BTM demand across • Geographic expansion with • Continued focus on expanding, burn and wound indications driven by demonstrate
Slide 15: polynovo.com
polynovo.com References: 1. Greenwood JE, Schmitt BJ, Wagstaff MJD. Burns Open. 2018;2(1):17-34. 2. Greenwood JE, Dearman BL. J Burn Care Res. 2012; 33:163-73. 3. Wagstaff MJD, Salna IM, Caplash Y, Greenwood JE. Burns Open. 2019; 3:12–30. 4. Greenwood JE, Wagstaff MJD, Rooke M, Caplash Y. Eplasty. 2